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S_ary Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic
agent for the treatment of cancer. Forty patients with bidinensionally measurable advanced adenocarcinoma
of the colon were treated with docetaxel lOOmgm 2 every 3 weeks as a I h infusion without routine
premedication. Thirty-nine patients were eligible: 23 males and 16 females. Median age was 60 years (range
41-75) and WHO performance status 1 (0-2). Prior adjuvant chemotherapy was performed in four patients
and prior radiotherapy in nine patients. Bidimensionally measurable disease sites included: liver in 26 patients,
lymph nodes and abdominal/peritoneal masses in 13, lung/mediastinal masses in ten and subcutaneous nodes
in four. The median number of cycles given was 2 (range 1-15). Thirty-three patients were evaluable for
response. One patient (3%) achieved a complete response and two (6%) (95% confidence limits 0-14%) a
partial response. Side-effects were similar to those observed in other studies. Docetaxel, given at this dosage
and schedule, has minimal activity in the treatment of colorectal carcinoma.
Colorectal carcinoma is one of the most frequent malignan-
cies in Europe and the second most common malignancy in
the United States, with more than 150,000 new cases diag-
nosed in the United States and 60,000 deaths per year (Bor-
ing et al., 1991). Surgical resection and more recently
adjuvant chemotherapy have become the standard approach
for early stage disease (Grem, 1991). However, approximately
20% ofpatients have metastases at the time ofdiagnosis, and
nearly 50% of patients will eventually develop metastatic
disease (Kemeny. 1987).
Systemic chemotherapy with 5-fluorouracil (5-FU)-based
therapy has been standard treatment for the last 30 years
with a response rate of 20% (Heiderberg et al., 1957;
Hansen, 1990). Newer therapeutic regimens are almost
always compared with 5-FU. However, no meaningful sur-
vival differences have been demonstrated when compared
with no treatment. Many 5-FU-containing combinations
have been investigated with poor overall response rates rang-
ing from 8% to 37% (Valone et al., 1989). Recently,
biochemical modulation of 5-FU with leucovorin has been
shown to improve the overall response rates compared with
5-FU alone (Erlichman et al., 1988; Petrelli et al., 1989; Poon
et al., 1989; Doroshow et al., 1990). Only few studies, how-
ever, have shown improvement in survival (Erlichman et al.,
1988; Petrelli, 1989; Hansen, 1990). A variety of other single
agents have only occasionally produced some tumour regres-
sion (Coehn et al., 1989; Bruckner, 1991). Since few truly
effective treatment options are available for advanced col-
orectal carcinoma, new and more effective agents are
urgently needed.
Paclitaxel (Taxol), extracted from the Pacific Yew Taxus
brevifolia (Wani et al., 1971), has been found to have
significant activity in several human malignancies, including
refractory ovarian cancer and breast cancer (McGuire et al.,
1989; Holmes et al., 1991). Docetaxel (Taxotere) is a taxoid
semisynthesised from a precursor extracted from the needles
of the European yew, Taxus baccata (Mangatal et al., 1989).
This source, in contrast to the source of paclitaxel, is
renewable, and docetaxel is formulated in polysorbate 80
instead of Cremophor EL, which is thought to be responsible
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for some of the side-effects of pacitaxel (Weiss et al.,
1990).
Docetaxel and paclitaxel both induce the formation of
stable microtubule polymers and thus disturb the architecture
of the cytoskeleton as well as the orderly progression through
mitosis (Ringel, 1991; Horwitz, 1992). Docetaxel is twice as
potent in the tubulin depolymerisation assay.
This mechanism of action differs from that of other spindle
poisons such as vinca alkaloids, which inhibit tubulin
assembly in microtubules. In preclinical testing, docetaxel
was active against three murine colon tumours, C38, C51 and
C26 (Geran et al., 1972), and the human tumour xenograft
CX-1 (Harrison et al., 1992).
In phase I studies, mucositis and neutropenia were dose
limiting. Mucositis was more frequently associated with
longer infusion schedules. The highest dose intensity could be
achieved with a 1 h infusion. The phase I study using this
dose intensity showed a maximum tolerated dose of
115mgm-2, and the recommended dose was 100mgm-2
once every 3 weeks. We performed a phase II study using
this dose and schedule for patients with advanced colorectal
carcinoma.
Patent and method
Eligibility criteria included histologically or cytologically
verified colorectal cancer with progression of disease. Eligible
patients had to have locally advanced, unresectable or meta-
static colorectal cancer. The presence of at least one bidimen-
sionally measurable lesion was required. WHO performance
status <2, life expectancy of > 12 weeks, absolute neutro-
phils >2,000ml-', platelets > 00,000 ml-', age >18 years
and <75 years, creatinine <140mmol11' (1.6mgdl ') or a
creatinine clearance >60 ml min-' bilirubin <1.25 x upper
normal limit, ASAT (SGOT) <2 x the upper normal limit
of 3 x in case of proven liver metastases were all neces-
sary.
No prior chemotherapy was allowed with the exception of
prior adjuvant chemotherapy, with a treatment-free interval
of at least 1 year. A minimum of 4-8 weeks after prior
radiotherapy was required; prior radiotherapy was not
allowed if it included the sole marker lesion. In all patients
written or oral informed consent was obtained.
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Pharmaceutical data
Docetaxel was provided as a sterile solution at a concentra-
tion of 40 mg ml-' in polysorbate 80 in 2 ml vials. Vials were
stored at 4C and protected from light. Immediately prior to
use the solution was diluted in the vial by using 6 ml ofeither
5% dextrose or 0.9% saline. The solution was then immedi-
ately shaken for 20 s using a vortex mixer to obtain a clear
solution. The appropriate amount of drug was then further
diluted in either 5% dextrose or 0.9% saline to a maximum
concentration of 1 mg ml-' docetaxel. This solution was
administered i.v. over 1 h.
Dosage and adninistration
Each cycle of treatment consisted of docetaxel 100 mg m-
administered as an intravenous infusion over 1 h every 3
weeks. Each patient was scheduled to receive all cycles of
treatment at the same dose. Doses were reduced for haemato-
logical and other toxicities. Adjustments were made accord-
ing to the organ system showing the most severe toxicity.
Toxicities were graded according to the common toxicity
criteria (CTC). In the case of grade 4 neutropenia or throm-
bocytopenia, and also in case of grade 2 skin toxicity, the
dose was reduced to 75% of the previous dose, i.e. to
75 mg m2 and 55 mg m'. If on treatment day 1 the neutro-
phil count was <1,500,l-' and platelets were <100,000gl-'
the dose was delayed for 1 week and subsequent dose adjust-
ment was made according to the nadir. Patients were
removed from the protocol if there was no recovery after 1
week.
Routine use of antiemetics was not allowed. In addition,
routine premedication was not used to prevent anaphylactoid
or hypersensitivity reactions. For mild symptoms such as
localised cutaneous reactions, pruritus and flushing the rate
of infusion was decreased until symptoms regressed. For
moderate symptoms such as generalised pruritus, flushing,
rash, dyspnoea or hypotension, the docetaxel infusion was
stopped and intravenous corticosteroids were given. For
severe symptoms, such as bronchospasm, generalised urticaria,
hypotension with systolic BP <80 mmHg or angio-oedema,
the infusion was stopped and steroids and antihistamines
were administered. Whenever possible docetaxel was resumed
within 3 h after recovery or the patient was reinfused within
72 h using premedication. In case of severe hypersensitivity
reactions all subsequent courses were preceded by a combina-
tion of dexamethasone and an antihistamine. Responses were
classified according to WHO criteria and assessed every two
courses. Treatment was continued until progression of
disease or the occurrence of unacceptable side-effects.
Results
Patient characteristics
Forty patients were entered into the study. Patient charac-
teristics are described in Table I. Four patients had under-
gone pnor adjuvant chemotherapy. All patients had bidimen-
sionally measurable lesions.
Response
Thirty-three patients were evaluable for response. One
patient was ineligible owing to concurrent use of cor-
ticosteroids. Six patients were inevaluable for response: three
of these patients received only one dose of docetaxel and
were not further evaluated for response. Of these three, two
patients had excessive toxicity, one patient had grade 4
neutropenia and one patient had grade 2 headaches. fever,
skin reaction and myelosuppression. The third patient had
gastrointestinal bleeding. Another patient was not evaluable
owing to violation of the protocol dose, and one patient did
not complete the second cycle and died from sepsis. An
additional patient died suddenly after two cycles prior to
evaluation of his disease. No autopsy was performed.
Table I Patient characteristics of 39 eligible patients treated with
docetaxel for colorectal cancer
Entered
Ineligible
Evaluable for response
Male:female
Median age (range) (years)
WHO performance status
median (range)
Prior surgery
Prior adjuvant chemotherapy
Prior immunotherapy
Prior radiotherapy
Bidimensionally measurable lesions
Liver
Lymph nodes and abdominal peritoneal
masses
Lung1mediastinal masses
Subcutaneous nodes
Median number of cycles (range)
40
1
33
23:16
60 (41-75)
1 (0-2)
35
4
9
9
26
13
10
4
2 (1-15)
Table H Side-effects (highest-CTC grade per patient)
CTC grade
1 2 3 4 Total (%)
Non-haematological toxicitY
Alopecia 8 26 34 (87)
Fatigue 8 14 5 27 (69)
Skin 6 18 24 (61)
Gastrointestinal
Nausea 12 3 2 17 (43)
Vomiting 6 5 11 (28)
Diarrhoea 6 9 1 16 (41)
Stomatitis 9 6 15 (38)
Neurotoxicity 9 4 1 14 (36)
Hypersensitivity reactions 7 1 3 2 13 (33)
Fever 5 8 13 (33)
Headache 5 4 9 (23)
Infections 3 3 2 8 (20)
Oedema 2 3 1 6(15)
Haematological toxicity
White blood cells 3 19 13 3 38 (97)
Neutrophils 5 6 27 38 (97)
Platelets 3 3 (8)
In one patient (3%) with liver metastases a complete re-
sponse lasting 54 weeks was obtained, two patients (6%)
(95% confidence limits 0-14%) attained a partial response
(PR) in liver metastases, nine (27%) patients had stable
disease and 21 (64%) progressed. The median time to pro-
gression in the evaluable patients was 1.5 months and the
median survival was 7.5 months. A total of 118 cycles of
docetaxel were administered. The median number of cycles
per patient was 2 (range 1-15). Twenty-seven patients had
no dose reduction. Twelve patients received 75 mg m- in 26
cycles, and two of these patients subsequently also received
55 mg m2 docetaxel in three cycles. Reasons for dose reduc-
tion were haematological toxicity (seven cycles), non-
haematological (mostly skin) toxicity (20 cycles) or both (two
cycles). The most frequent reason for a patient to go off
study was tumour progression.
Toxicity
The most important side-effects are described in Table II,
based on 39 eligible patients. Alopecia was almost universal
(87%). Grade 3-4 leucopenia occurred in 16 (41%) patients
and grade 3-4 neutropenia in 85% of patients. Coinciding
sepsis was reported in only one cycle; five patients required
antibiotics for mild infections during neutropenia, each dur-
ing one cycle. Mild to moderate skin toxicity was seen in 24
(61%) patients. This most commonly consisted of dry skin,
erythema, pruritus, maculas, papulas and nail changes. Six378 C.N. STERNBERG et al.
(15%) patients developed fluid retention, which was most
often peripheral oedema. Mild to moderate neurosensory
toxicity was observed in 13 patients (33%), neuromotor toxi-
city in only one. Fatigue occurred in 27 (69%) patients.
Hypersensitivity reactions were seen in 19 cycles (16%).
These were mostly mild. The majority of hypersensitivity
reactions occurred during cycle 1, within the first 5 min.
Gastrointestinal side-effects included mild to moderate
nausea in 17 (43%) patients, vomiting in 11 (28%), diarrhoea
in 16 (41%), and mild to moderate stomatitis in 15
(38%).
Discusio
The toxicities observed with docetaxel in this phase II study
were similar to those observed in the treatment of patients
with other solid tumours (Verweij et al., 1994). Reversible
alopecia was practically universal and occurred within 2-4
weeks after the start of therapy. Hypersensitivity reactions, as
have been observed with other taxoids, were relatively infre-
quent and were rarely severe despite the fact that no routine
premedication was used. Premedication including corti-
costeroids and antihistamines further reduces the incidence of
these reactions (Schrijvers et al.. 1993). Other toxicities were
similar to those observed with paclitaxel. Additional toxci-
cities included a pruritic skin eruption and peripheral
oedema. Skin toxicity consisted of erythema, desquamation
and infrequent exfoliation or presented as nail toxicity with
calcification and onycholysis. These toxicities were not
reduced by the routine use of corticosteroids (Wanders et al.,
1993). Fluid retention was most probably related to the
cumulative dose of docetaxel, occurring infrequently at
cumulative doses below 400 mg m-' (Wanders et al.,
1993).
In phase II studies docetaxel has already been shown to
have anti-tumour activity in breast cancer, non-small cell
lung cancer, ovarian cancer. soft-tissue sarcoma, head and
neck cancer, gastric cancer and melanoma (Verweij et al.,
1994). No activity was seen in renal cancer (Bruntsch et al.,
1993). Based upon the results of this study and the study of
Pazdur et al. (1994), docetaxel, like pacitaxel, has minimal
activity in the treatment of colorectal carcinoma. One
mechanism conferring resistance to docetaxel and paclitaxel
is the multidrug resistance P-glycoprotein, although the
clinical relevance of this in colorectal cancer is uncertain
(Lehnert et al., 1992). Treatment of advanced colorectal car-
cinoma will require further study with new agents in view of
its insensitivity to most available cytotoxic drugs.
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